Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock Company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

ANNOUNCEMENT IN RELATION TO GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

Reference is made to the announcement of Jenscare Scientific Co., Ltd. (the "**Company**") dated November 19, 2026 in relation to the issuance of the Filing Notice by the CSRC in respect of the Company's H Share Full Circulation application (the "**Announcement**"). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

LISTING APPROVAL BY THE STOCK EXCHANGE

The board of directors (the "**Directors**") of the Company is pleased to announce that the Company had made application to the Listing Committee of the Stock Exchange for the approval (the "**Listing Approval**") of the listing of and the permission to deal in 74,227,021 H Shares (the "**Converted H Shares**") to be converted from 74,227,021 unlisted shares of the Company (the "**Unlisted Shares**") held by the Participating Shareholders (as defined below) under the Conversion and Listing. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on November 26, 2026.

Shareholding Structure

The Conversion and Listing will involve a total of 10 participating holders of 74,227,021 Unlisted Shares and the number of the Converted H Shares held by such participating holders represents approximately 17.79% of the total issued shares of the Company.

The table below sets out the shareholding percentage of the participating shareholders in the Company in relation to the Converted H Shares upon completion of the Conversion and Listing.

Name of the participating shareholders (the "Participating Shareholders") of the Unlisted Shares	**Number of Unlisted Shares converted to H shares**	**Approximate percentage of total issued shares of the Company upon completion of the Conversion and Listing** *(%)*
Lv Shiwen	19,627,920	4.71
Ningbo Mukang Venture Capital Partnership (Limited Partnership) (寧波沐康創業投資合夥企業(有限合夥))	12,945,420	3.10
Hainan Hualing Investment L.P. (Limited Partnership) (海南華翎投資合夥企業(有限合夥))	16,363,620	3.92
Shanghai Shidi Industrial Development Co., Ltd. (上海仕地實業發展有限公司)	11,810,448	2.83
Suzhou Chenzhide Investment L.P. (Limited Partnership) (蘇州辰知德投資合夥企業(有限合夥))	4,254,120	1.02
Suzhou Bilinxing Venture Capital Partnership (Limited Partnership) (蘇州比鄰星創業投資合夥企業(有限合夥))	1,870,200	0.45
Shanghai Changxiang Medical Technology Center (Limited Partnership) (上海暢想醫療科技中心(有限合夥))	581,832	0.14
Duckling Fund, L.P.	1,723,501	0.41
FOREBRIGHT KEEN ASCENT LIMITED	1,050,000	0.25
Beijing People's Renbao Health Industry Investment Fund (Limited Partnership) (北京人保健康養老產業投資基金(有限合夥))	3,999,960	0.96
Total	**74,227,021**	**17.79**

Note: The percentages have been rounded to two decimal places. Therefore, the total percentage may not equal to the total percentage shown.

Upon completion of the Conversion and Listing, the share capital structure of the Company will be as follows:

Class of shares	**As at the date of this announcement**		**Upon completion of the Conversion and Listing**	
	Number of shares	*Approximate percentage %*	*Number of shares*	*Approximate percentage %*
H shares	310,306,209	74.38	384,533,230	92.18
Unlisted shares	106,861,081	25.62	32,634,060	7.82
Total	**417,167,290**	**100.00**	**417,167,290**	**100.00**

Note: The percentages have been rounded to two decimal places. Therefore, the total percentage may not equal to the total percentage shown.

The Company will comply with the requirements under the Listing Rules and applicable laws to complete relevant conversion and trading procedures in respect of the Converted H Shares and make further announcement(s) on the progress of the Conversion and Listing, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, November 26, 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.